BIOINDUSTRY PARK SILVANO FUMERO SPA SOCIETA'BENEFIT

Their core work

Bioindustry Park Silvano Fumero is an Italian life sciences science and technology park located in Colleretto Giacosa, near Turin in the Canavese biotech corridor. They provide infrastructure, expertise, and a commercialization ecosystem for biotech companies and research teams, with a hands-on focus on bridging laboratory-stage science and industrial scale-up. In EU projects, they contribute as a specialist partner — offering bioprocess expertise, formulation know-how, and a direct route to spin-off creation and economic maturation of research results. Their participation spans both agricultural biotech (biopesticide development and biocontrol scale-up) and life sciences medtech (safety testing for nanotechnology-enabled medical devices).

What they specialise in

How they've shifted over time

In their first H2020 engagement (2017, IPM-4-Citrus), Bioindustry Park was focused squarely on agricultural biotech — specifically biopesticide production using Bacillus thuringiensis, scale-up processes, and getting biocontrol products through field validation to market readiness. By 2019, their second project (SAFE-N-MEDTECH) signals a clear pivot toward medical technology, with involvement in nano-enabled medical devices and in vitro diagnostics safety testing. The shift from agri-biotech to medtech safety suggests the park is broadening its portfolio to serve the full spectrum of life sciences companies it hosts, rather than remaining a niche agricultural biotech partner.

They are moving from agricultural biotech toward medical device safety and nanotechnology, positioning the park as a broader life sciences ecosystem player rather than a specialist agri-biotech partner.

How they like to work

Bioindustry Park has never coordinated an H2020 project — both roles are as participant or third party — indicating they join projects led by others and contribute specific infrastructure or expertise rather than driving research agendas. Despite only two projects, they have engaged with 45 distinct partners across 19 countries, meaning they participate in large international consortia where their park infrastructure and commercialization pathways add value to the broader team. For a prospective partner, this means a straightforward engagement: they deliver well-defined contributions (bioprocess expertise, tech transfer support) without the overhead of consortium management.

Forty-five unique consortium partners across 19 countries from just two projects reflects participation in large, geographically diverse EU consortia rather than a tightly curated bilateral network. Their partnerships span both MSCA-RISE mobility networks and Innovation Actions, suggesting exposure to academic, industrial, and SME partners alike.

What sets them apart

Bioindustry Park Silvano Fumero is not a research institute doing science — it is a commercialization infrastructure for science done by others, which makes it a rare and valuable consortium partner when a project needs a credible route from lab to market. Their explicit keyword focus on "economic maturation" and "spin-off" distinguishes them from universities or research centers that stop at publication. For any consortium building a project with a strong exploitation and go-to-market component in life sciences, this park offers both the physical infrastructure in northern Italy's biotech corridor and the commercial ecosystem to give that exploitation chapter real substance.

Highlights from their portfolio

• IPM-4-Citrus
  Their only directly funded H2020 project, covering the full biocontrol pipeline from Bacillus thuringiensis production through bioprocess scale-up to field validation and spin-off creation — a rare cradle-to-market scope in agricultural biotech.
• SAFE-N-MEDTECH
  Marks a strategic pivot into nano-enabled medical technologies safety testing, demonstrating the park's ability to serve the medtech industry and not just agri-biotech — significant for understanding their current positioning.